Abstract
In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.
Keywords: Cell therapy, disease modeling, induced pluripotent stem cells, reprogramming, tissue regeneration, tissue engineering.
Current Stem Cell Research & Therapy
Title:Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling
Volume: 9 Issue: 2
Author(s): Graham G. Walmsley, Jeong Hyun, Adrian McArdle, Kshemendra Senarath-Yapa, Michael S. Hu, Michael T. Chung, Victor W. Wong, Michael T. Longaker and Derrick C. Wan
Affiliation:
Keywords: Cell therapy, disease modeling, induced pluripotent stem cells, reprogramming, tissue regeneration, tissue engineering.
Abstract: In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.
Export Options
About this article
Cite this article as:
Walmsley G. Graham, Hyun Jeong, McArdle Adrian, Senarath-Yapa Kshemendra, Hu S. Michael, Chung T. Michael, Wong W. Victor, Longaker T. Michael and Wan C. Derrick, Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling, Current Stem Cell Research & Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574888X09666131217004137
DOI https://dx.doi.org/10.2174/1574888X09666131217004137 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design Protein-mediated Fatty Acid Uptake in the Heart
Current Cardiology Reviews Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Strain and Strain Rate Imaging by Echocardiography - Basic Concepts and Clinical Applicability
Current Cardiology Reviews Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design High Fidelity SNP Genotyping Using Sequence-Specific Primer Elongation and Fluorescence Correlation Spectroscopy
Current Pharmaceutical Biotechnology “Seeing is Believing”: Perspectives of Applying Imaging Technology in Discovery Toxicology
Combinatorial Chemistry & High Throughput Screening Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets